Microsatellite instability in endometrial cancer: the role of diagnostic methods and their clinical application. Expert consensus
Deficient DNA mismatch repair (dMMR) is a rare molecular disorder found in 20-30 % of endometrial tumors. Laboratory identification of dMMR/microsatellite instability (MSI) has a high diagnostic value, since these impairments are considered as biomarkers of endometrial adenocarcinoma. They help to i...
Saved in:
Main Authors: | A. S. Tyulyandina, E. A. Ulrikh, L. A. Kolomiets, S. E. Krasilnikov, A. G. Kedrova, A. A. Rumyantsev, G. A. Raskin, A. I. Nesterova, M. V. Volkonskiy, O. N. Churuksaeva, A. Yu. Goryainova, V. V. Zhavoronkova, V. N. Dmitriev, S. T. Nazranova, A. V. Shkradyuk, K. S. Volkova, A. I. Arutyunova, S. N. Kunitskaya, L. V. Stepura, T. G. Zolotoreva, E. B. Shakhnovich, E. V. Ponomareva, M. A. Strokova, A. S. Danilova, E. S. Martynova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2023-05-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/1039 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Expanding therapeutic opportunities for progressive uterine cancer: clinical experience
by: A. G. Kedrova, et al.
Published: (2022-05-01) -
Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01) -
The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
by: A. E. Protasova, et al.
Published: (2024-11-01) -
Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2024-01-01) -
Efficacy and safety of lenvatinib plus pembrolizumab in patients with endometrial cancer: data from an extended study of routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2025-03-01)